Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Placental growth factor also plays a role in chronic myeloid leukemia

Placental growth factor also plays a role in chronic myeloid leukemia

QIAGEN to acquire Ipsogen

QIAGEN to acquire Ipsogen

Researchers investigate the role of PlGF in mice with chronic myeloid leukemia

Researchers investigate the role of PlGF in mice with chronic myeloid leukemia

JEM published paper identifies new gene mutations in patients with chronic lymphocytic leukemia

JEM published paper identifies new gene mutations in patients with chronic lymphocytic leukemia

Astellas, Ambit Biosciences announce interim results from AC220 Phase 2 trial against AML

Astellas, Ambit Biosciences announce interim results from AC220 Phase 2 trial against AML

Formaldehyde & other chemicals declared carcinogenic: Report

Formaldehyde & other chemicals declared carcinogenic: Report

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

HHS adds eight substances to 12th Report on Carcinogens

HHS adds eight substances to 12th Report on Carcinogens

Incyte announces additional results from ruxolitinib Phase III trial on myelofibrosis

Incyte announces additional results from ruxolitinib Phase III trial on myelofibrosis

Scientists pioneer way to find more chromosomal aberrations in tumors

Scientists pioneer way to find more chromosomal aberrations in tumors

Ambit Biosciences raises $30 million through Series D-2 equity financing

Ambit Biosciences raises $30 million through Series D-2 equity financing

Blinatumomab phase 2 trial results on acute lymphoblastic leukemia to be presented at EHA 2011

Blinatumomab phase 2 trial results on acute lymphoblastic leukemia to be presented at EHA 2011

UAB acquires first cell-processing workstation from SANYO

UAB acquires first cell-processing workstation from SANYO

Valuable insight into how people develop B-cell lymphoma

Valuable insight into how people develop B-cell lymphoma

UAB first in U.S. with cell-processing workstation

UAB first in U.S. with cell-processing workstation

NYU Cancer Institute scientists present new research findings at ASCO 2011

NYU Cancer Institute scientists present new research findings at ASCO 2011

Study identifies factors that increase bankruptcy risk among people with common cancers

Study identifies factors that increase bankruptcy risk among people with common cancers

Telik initiates Telintra Phase 2 trial in Revlimid refractory or resistant, del 5q MDS

Telik initiates Telintra Phase 2 trial in Revlimid refractory or resistant, del 5q MDS

LLS announces four new Academic Concierge partnerships for cancer drug development

LLS announces four new Academic Concierge partnerships for cancer drug development

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.